Anticoagulation in atrial fibrillation: delayed implementation of evidence A trial fibrillation (AF) is a common heart rhythm disorder whereby deranged electrical impulses in the atria prevent effective atrial contractions, allowing blood to pool with the potential formation of emboli. Approximately 1-2% of the general population is affected. Symptoms may include palpitations, shortness of breath, fatigue and lethargy but people may be asymptomatic or unaware that they have the condition.
While the condition itself is not life-threatening, AF-related ischaemic stroke is of particular concern and evidence suggests that stroke risk remains constant whether the individual has prolonged, permanent or paroxysmal AF (Friberg et al, 2010) . One in five strokes is attributed to this arrhythmia and these are more likely to be fatal than other causes of stroke, with survivors more severely disabled (Camm et al, 2010) . Assessment of stroke risk in people with AF was previously calculated using CHADS2 to identify risk factors associated with a higher incidence of stroke (Camm et al, 2010) .
However, this evolved into a more sensitive instrument, the CHA2DS2-VASc (Lip et al, 2010; Olesen et al, 2011) to inform stroke risk calculation and thus support prescribing decisions regarding the need for anticoagulation. The acronym and scoring system are explained in Table 1 .
A score of one or more in the CHADS2 or ≥2 in the CHA2DS2-VASc means that thromboprophylaxis is indicated. Use of tools to assist with assessment of bleeding risk such as the HAS-BLED score (Pisters et al, 2010 ) is also recommended to further inform the risk/benefit ratio for both patients and prescribing clinicians (Camm et al, 2010) .
Therefore, the focus of assessment and treatment for individuals with AF is not only aimed at controlling or relieving symptoms, but also at reducing stroke risk through identification of individuals who would benefit from thromboprophylaxis. Evidence regarding what is considered most effective in this regard has previously supported use of aspirin (National Institute for Health and Care Excellence (NICE), 2006; Camm et al, 2010) .
However, evidence for benefits of aspirin, either alone or in combination with other antiplatelet agents, to reduce stroke risk is weak-yet, its potential to increase risk of bleeding is similar to that of anticoagulants (Camm et al, 2012) . Thus revised European guidelines in 2012 strongly Jenny Tagney, Cardiology Nurse Consultant, The Bristol Heart Institute, Bristol. Email: jenny.tagney@uhbristol.nhs.uk recommended use of anticoagulants, with aspirin use reserved only for people who refused these (Camm et al, 2012) . While previously warfarin was the only anticoagulant available, requiring frequent blood testing to monitor individual clotting levels threatening concordance, the development of novel non-vitamin-K antagonist anticoagulants provides a more acceptable, yet still cost-effective alternative (NICE, 2014a) . However, as these medications are relatively new additions to national prescribing formulary and currently only licensed for use in patients with non-valvular AF, familiarity and confidence regarding their use may take some time to develop.
In light of the potential to reduce the risk of stroke if AF is detected and anticoagulation commenced, significant work has been undertaken in the UK to improve knowledge and awareness of both assessment and treatment. GRASP-AF is an audit tool developed to assist primary care practices in identifying patients diagnosed with AF via their practice records (NHS Improving Quality (NHSIQ), 2012). The tool is designed to ensure that practices are compliant with requirements of the Quality
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if there might be a rhythm disturbance. His pulse was regular in clinic and his electrocardiogram (ECG) showed sinus rhythm. To investigate further, the author arranged for an ambulatory cardiac monitor to assess for any arrhythmias.
When the results of this were analysed, episodes of paroxysmal AF were demonstrated. In applying the CHA2DS2-VASc scoring system (Lip, 2011), he scored two-one point for hypertension and one for his age (range 65-74). Thus he met primary stroke prevention criteria for anticoagulation, which was explained to him via a letter that was copied to his GP requesting that this was commenced. Mr Bloggs telephoned a week or so after the letter was sent to say that after discussion with his GP, they had decided that he only really needed aspirin as, according to his CHADS2 score of one (for hypertension), he was only at low risk of stroke.
As a result of current specialist knowledge, it was possible to effectively explain to Mr Bloggs why aspirin was no longer recommended and identify how the evidence that he and his GP were employing had been updated. Further, owing to an awareness of the existence of conflicting guidance for GPs, it was possible to identify precisely where the error in information occurred. Mr Bloggs was grateful for further explanations but requested that a further letter be written to him and his GP including additional information to guide the prescription of anticoagulation.
Discussion
It is not usual practice in all cardiac centres to bring patients back to secondary care when results of investigations are reported unless any ensuing treatment requires initiation within a secondary care setting. However, as can be seen from the case study of Mr Bloggs, this can mean that there is insufficient opportunity to engage in an open dialogue with patients regarding proposed treatment options and an over-reliance on primary care clinicians to provide this. The term 'shared decision making' (SDM) is used to describe clinical decisions arising from discussions between clinicians and patients regarding proposed treatment. Key components of SDM are identified as providing (Elwyn et al, 2012) : w Information w Opportunities to explore and deliberate options with patients w Support for patients to make an informed choice regarding the option that best suits them. However, within this example, it seems that correspondence and collaboration with Mr Bloggs' GP may also have benefitted from the SDM approach. The decision reached by Mr Bloggs and his GP after receiving recommendations based on an investigating clinician's analysis suggests that insufficient evidence had been provided to support the rationale to either Mr Bloggs or his GP. Good communication and ensuring evidence-based practice are key standards within the NMC (2006) standards for prescribing.
Outcomes Framework (QOF) (NHS Employers, 2013). These requirements included identifying patients with AF and ensuring that they were treated according to current guidelines. Within this framework, the CHADS2 scoring system (rather than the more sensitive CHA2DS2-VASc system) and use of aspirin were still recommended in 2013/14, stating that this was 'in accordance with ESC guidelines' (citing the 2010 guidance) despite revised guidance from the ESC being published in 2012.
Thus, despite updated empirical evidence that antiplatelets were not effective in stroke prevention in patients with AF, GPs were still incentivised to prescribe them. In July 2014, NICE also released revised guidelines for the assessment and management of AF that specifically recommended against prescribing aspirin for stroke prevention in AF (NICE, 2014b) . It is against this background that the following case study is set.
Case study
Mr Bloggs (pseudonym) was a 67-year old man who was referred to a cardiology clinic by his GP. Mr Bloggs was a lifelong non-smoker but was treated for hypertension.
In describing his symptoms, Mr Bloggs mentioned occasions where he felt his pulse `race' , with a fluttering feeling in his chest. While these symptoms were not particularly troublesome, he mentioned them as he wondered
Policy in Practice
As AF is such a common condition and there had been local educational efforts aimed at updating GPs' knowledge and awareness of assessment and treatment, a more cooperative response was anticipated from this GP. However, such educational efforts may not reach all GPs. Therefore, any guideline is only effective if clinicians are aware of and implement its content, which can cause both delays in treatment initiation and inappropriate prescribing practice. In England, GPs' practice is guided by the QOF (NHS Employers, 2013), which is apparently not quickly responsive to changes in evidence.
If GPs are aware of updated evidence, they may choose to incorporate this as a principle of 'best practice' , yet their 'performance' in relation to the QOF would be penalised if they do. Therefore, in order to ensure that primary care clinicians are kept abreast of specialist practice developments, it seems that a two-pronged approach may be indicated.
From a policy perspective, it is essential that there is timely communication between relevant policy development bodies and practice governing bodies such as NICE, NHS England and speciality guideline development groups to ensure such conflicting guidance does not jeopardise safe prescribing. From a personal responsibility perspective, this issue has been discussed within local cardiology clinical forums. An agreed development is that, specifically where such potential conflicts have been identified, a one-page printed overview of the updated clinical guidance will be provided with references for further reading by primary care clinicians if desired.
However, there remains the potential for guidance from specialists to be ignored unless there is a willingness among non-specialist clinicians to engage and a shared understanding of what constitutes best practice. Barriers to implementation of specialist guidelines in primary care settings are also not limited to AF (Grol, 2001; Chenot et al, 2008) .
In anticipation of potential barriers to implementation of the new NICE (2014b) AF guidelines, an implementation collaborative consensus document was developed as part of the implementation programme focusing on the exclusion of aspirin from treatment options and supporting novel non-vitamin-K antagonist anticoagulants (NICE, 2014a) . This brings together the evidence for anticoagulation in non-valvular AF and adopts a 'frequently asked questions' approach to how information is presented. Still, it is not clear how many primary care clinicians this information may reach and further, how many will feel confident to incorporate it into their practice.
Therefore, it seems that a multifaceted approach is likely to be most effective in ensuring that new guidance is both highlighted and implications for practice explained to non-specialist clinicians. Wherever possible, this should include direct communication regarding a specific patient so that practical issues relating to that individual may be considered. Additionally, providing practice nurses and practice managers with easy to follow summaries of new treatment guidelines may further support both patients and GPs. Finally, it is imperative to ensure that the patient is fully cognisant of treatment indications and any available options so that they are empowered to guide their own treatment and everyone is clear regarding their choice.
This case study has identified that lack of up-to-date specialist knowledge and delays in implementing clinical guidelines in primary care may give rise to conflicting information being given to patients regarding most effective treatment. While specialist nurses can act to facilitate education and raise awareness to an extent, it will be difficult to ensure that such approaches reach every relevant clinician or that those clinicians will feel confident to change their practice. Shared decision making models may help to ensure that both individual patients and their primary care clinicians are provided with information and opportunities to explore potential options through direct discussion with a specialist clinician. Through this collaborative approach, it is anticipated that patients will feel supported in their treatment choices and non-specialist clinicians will feel supported in implementing recommendations from clinical guidelines. 
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